The aim of this study was to evaluate the ocular tear interleukin (IL)-6 and IL-8 concentrations within the first 6 months of contact lens (CL) wear in eyes of neophyte CL users who had been commenced on either silicone hydrogel CL (SH-CL) or conventional hydrogel CL (CH-CL).
Twenty-four subjects with no history of CL wear received either SH-CL (n=12) or CH-CL (n=12) for a period of 6 months in this prospective study. Tear IL-6 and IL-8 concentrations were determined before CL wear (0 months) and at 1, 3, and 6 months after CL commencement. The sera of all the subjects were tested and graded (grades 0–6) for grass, weed, and tree pollen–specific immunoglobulin E (IgE) levels.
Tear IL-6 concentrations at 0, 1, 3, and 6 months for SH-CL and CH-CL users were 7.1±6.4, 10.5±8.9, 18.6±17.0, 33.1±15.0 pg/mL and 10.9±8.2, 6.4±4.0, 24.2±13.2, 34.4±17.5 pg/mL, respectively. In both groups, IL-6 levels were significantly elevated at 6 months compared with those at 0 months (P<0.001). Tear IL-8 concentrations at 0, 1, 3, and 6 months for SH-CL and CH-CL users were 107.4±56.8, 106.0±47.4, 319.5±154.8, 412.6±104.1 pg/mL and 176.4±59.7, 196.2±145.0, 410.7±121.2, 456.7±19.2 pg/mL, respectively. In both groups, tear IL-8 levels were significantly elevated at 6 months compared with those at 0 months (P<0.001). The tear IL-6 and IL-8 levels were found to be similar within the 2 groups at the 6-month time point (P>0.05). The serum grass, weed, and tree pollen–specific IgE levels were similar between groups (P>0.05) and less than 0.35 kU/L (grade 0) in 22 of 24 (91.7%) participants tested.
The SH-CL and CH-CL wear is associated with elevation of IL-6 and IL-8 levels in the tears of healthy, nonatopic neophyte CL users.
Department of Ophthalmology (C.P., M.I., M.C.M.), Hacettepe University School of Medicine, Ankara, Turkey.
Address correspondence and reprint requests to Dr. Murat İrkec, Department of Ophthalmology, Hacettepe Üniversitesi, Göz Hastalıkları Anabilim Dalı, Sıhhiye 06100, Ankara, Turkey; e-mail: email@example.com
The authors have no funding or conflicts of interest to disclose.
Accepted December 23, 2011